PAWR

PAWR (Par-4) is a pro-apoptotic regulator that acts as a molecular switch converting autophagy to apoptosis in cancer cells (PMID:25803782). It suppresses BCL2 and BECN1 expression and disrupts the BCL2-BECN1 interaction; cells lacking PAWR fail to make this switch and instead accumulate abundant autophagy even under toxic stress, establishing PAWR as essential for the autophagy-to-apoptosis transition (PMID:25803782). Beyond this switching function, the mechanistic detail of how PAWR engages downstream signaling has not been dissected in the available corpus; its C-terminal domain, which mediates interactions with apoptotic partners, is consistent with an intrinsically disordered protein but has only been characterized at preliminary crystallographic resolution (PMID:25195896).

1. 2014 Low

   Addressed how Par-4 physically engages apoptotic partners by structurally characterizing its interaction-bearing region, establishing that the C-terminal domain mediates these contacts and is consistent with intrinsic disorder.

   Evidence Expression, purification, and X-ray crystallography of the rat Par-4 C-terminal domain to 3.7 Å

   PMID:25195896

   Open questions at the time

   • Only preliminary diffraction data collected; no refined structure or model deposited
   • No functional validation of specific partner-binding residues in this report
   • Human PAWR domain structure not solved
2. 2015 Medium

   Resolved whether PAWR is merely correlated with cell death or causally required for switching cellular fate, showing it is essential to convert cytoprotective autophagy into apoptosis by suppressing BCL2/BECN1 and disrupting their interaction.

   Evidence pawr-knockout MEFs (loss-of-function) plus overexpression rescue, BCL2-BECN1 co-immunoprecipitation, and autophagy/apoptosis marker western blots in prostate cancer cells

   PMID:25803782

   Open questions at the time

   • Mechanism by which PAWR suppresses BCL2/BECN1 transcription or stability not defined
   • Direct vs indirect disruption of the BCL2-BECN1 interface not distinguished
   • Single-lab finding without independent replication
3. 2021 Low

   Tested whether restoring PAWR expression is sufficient to drive apoptosis and whether this extends beyond prostate cancer, showing transcriptional upregulation induces apoptosis and cell cycle arrest across prostate and bladder cancer cells with associated NF-κB/Akt inactivation, BCL-2 loss, and caspase activation.

   Evidence saRNA-mediated promoter activation of PAWR, western blots for NF-κB/Akt/BCL-2/caspase/PARP, viability and apoptosis assays, and cisplatin cooperation

   PMID:26797252 PMID:34220332

   Open questions at the time

   • No direct mechanistic link showing how PAWR engages NF-κB or Akt
   • Pathway changes are correlative readouts, not demonstrated direct targets
   • Single method category without genetic confirmation

• How PAWR mechanistically couples to NF-κB and Akt signaling, and the identity and structure of its direct apoptotic binding partners, remain unresolved.
• No refined high-resolution structure of the partner-binding domain
• Direct molecular partners not biochemically defined in the corpus
• Causal chain from PAWR to NF-κB/Akt inactivation not established